Distinguishing the anti-proliferative functions from the pro-metastatic functions of TGFβ reveals KLF10 to be a potential target for the development of therapies for cancers with aberrant TGFβ pathways, such as PDAC [6]. This evidence concerns the gene KLF10 and cancer.